MetLife Investment Management’s Janux Therapeutics JANX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $552K | Buy |
23,876
+5,213
| +28% | +$120K | ﹤0.01% | 1628 |
|
|
2025
Q1 | $504K | Buy |
18,663
+1,365
| +8% | +$36.9K | ﹤0.01% | 1724 |
|
|
2024
Q4 | $926K | Buy |
17,298
+949
| +6% | +$50.8K | 0.01% | 1455 |
|
|
2024
Q3 | $743K | Hold |
16,349
| – | – | ﹤0.01% | 1564 |
|
|
2024
Q2 | $685K | Buy |
16,349
+7,288
| +80% | +$305K | ﹤0.01% | 1546 |
|
|
2024
Q1 | $341K | Sell |
9,061
-1,553
| -15% | -$58.5K | ﹤0.01% | 1900 |
|
|
2023
Q4 | $114K | Hold |
10,614
| – | – | ﹤0.01% | 2542 |
|
|
2023
Q3 | $107K | Hold |
10,614
| – | – | ﹤0.01% | 2545 |
|
|
2023
Q2 | $126K | Hold |
10,614
| – | – | ﹤0.01% | 2547 |
|
|
2023
Q1 | $128K | Hold |
10,614
| – | – | ﹤0.01% | 2452 |
|
|
2022
Q4 | $140K | Hold |
10,614
| – | – | ﹤0.01% | 2447 |
|
|
2022
Q3 | $144K | Hold |
10,614
| – | – | ﹤0.01% | 2485 |
|
|
2022
Q2 | $130K | Hold |
10,614
| – | – | ﹤0.01% | 2589 |
|
|
2022
Q1 | $152K | Buy |
10,614
+5,312
| +100% | +$76.2K | ﹤0.01% | 2509 |
|
|
2021
Q4 | $105K | Hold |
5,302
| – | – | ﹤0.01% | 2392 |
|
|
2021
Q3 | $115K | Buy |
+5,302
| New | +$115K | ﹤0.01% | 2380 |
|